Despite this correlation, one study on the effects of tocilizumab (monoclonal antibody against IL-6) demonstrated no change in T cell phenotype between the treatment and placebo groups in newly diagnosed T1D patients [100]. The gene discussed is IL6; the disease is type 1 diabetes mellitus.